Adlai Nortye (NASDAQ:ANL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Adlai Nortye (NASDAQ:ANL) to a hold rating in a research report sent to investors on Saturday morning.

ANL has been the subject of several other research reports. HC Wainwright upgraded shares of Adlai Nortye from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research note on Friday, February 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Adlai Nortye in a research note on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $16.00.

Adlai Nortye Stock Performance

NASDAQ ANL opened at $8.79 on Friday. The company’s fifty day moving average is $6.07 and its two-hundred day moving average is $3.16. Adlai Nortye has a 52-week low of $0.88 and a 52-week high of $12.09.

About Adlai Nortye

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.